South Korea-based ImmunoForge Co Ltd, a clinical-stage biopharmaceutical company focused on developing therapies for rare, neuromuscular, metabolic diseases, and targeted oncology, announced on Thursday that its executive management team will participate in BIO-Europe 2026, held in Cologne, Germany, from November 9 to 11, 2026.

During the conference, ImmunoForge will engage in 1-on-1 partnering sessions with global pharmaceutical leaders to present its core drug delivery platform technologies and advance Licensing-Out (L/O) and global co-development discussions for its lead clinical-stage oncology and rare disease pipelines.

ImmunoForge leverages its proprietary ELP (Elastin-Like Polypeptide) and LMT (Leptin Receptor-Mediated Transcytosis) drug delivery platforms to develop next-generation biologics and innovative small molecules with enhanced stability, prolonged half-life, and targeted tissue delivery.